| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2004 | CA2231632C Use of creatine analogues for the treatment of disorders of glucose metabolism |
| 01/20/2004 | CA2208322C Directly compressible high load acetaminophen formulations |
| 01/20/2004 | CA2174104C Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 01/20/2004 | CA2165984C Compounds for the photodecontamination of pathogens in blood |
| 01/20/2004 | CA2157323C Gepirone dosage form |
| 01/20/2004 | CA2140254C Controlled release morphine preparation |
| 01/20/2004 | CA2123051C Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments |
| 01/20/2004 | CA2122780C Use of selegilin in veterinarian medicine |
| 01/20/2004 | CA2120751C Trimethoprim oral liquid |
| 01/20/2004 | CA2116782C 1-substituted 1h-imidazo¬4,5-c|quinolin-4-amines; intermediate and pharmaceutical compositions |
| 01/20/2004 | CA2110335C Process for producing n4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| 01/20/2004 | CA2108356C Antibiotic compounds |
| 01/20/2004 | CA2089441C Process for the preparation of cephem prodrug esters |
| 01/20/2004 | CA2052532C Hardening agent for affected tissues of the digestive system |
| 01/18/2004 | CA2431745A1 External preparation for treating dermatosis and pruritus due to hemodialysis |
| 01/17/2004 | CA2435399A1 New anthracene derivatives and their use as pharmaceutical preparations |
| 01/15/2004 | WO2004005544A2 Marker genes for determining renal toxicity |
| 01/15/2004 | WO2004005513A2 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 01/15/2004 | WO2004005510A1 NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF |
| 01/15/2004 | WO2004005509A1 Method of examining allergic disaese and drug for treating the same |
| 01/15/2004 | WO2004005494A1 Medium for culturing autologous human progenitor stem cells and applications thereof |
| 01/15/2004 | WO2004005472A2 Inhibitors of ftsz and uses thereof |
| 01/15/2004 | WO2004005457A2 Tfc/ beta-catenin regulated genes for treating cancer |
| 01/15/2004 | WO2004005423A1 Allergen inactivator |
| 01/15/2004 | WO2004005323A2 Affinity small molecules for the epo receptor |
| 01/15/2004 | WO2004005321A2 Methods of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system |
| 01/15/2004 | WO2004005314A1 ESTRIENO[3,2-b]/[3,4-c]PYRROLE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS |
| 01/15/2004 | WO2004005313A2 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 01/15/2004 | WO2004005311A1 Bafilomycin-like metabolite from a novel micromonospora species |
| 01/15/2004 | WO2004005310A2 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | WO2004005309A2 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | WO2004005304A1 Ruthenium anticancer complexes |
| 01/15/2004 | WO2004005301A1 Substituted aryl boronic acids, their preparation and their precursors |
| 01/15/2004 | WO2004005299A1 Polymorphic forms of a 4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivative |
| 01/15/2004 | WO2004005296A1 Novel derivative of flavone c-glycoside and composition containing the same |
| 01/15/2004 | WO2004005295A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 01/15/2004 | WO2004005293A2 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 01/15/2004 | WO2004005291A1 Hetero-cyclicaly substituted imidazotriazines |
| 01/15/2004 | WO2004005290A1 Substituted imidazotriazines |
| 01/15/2004 | WO2004005286A2 Viral inhibitors |
| 01/15/2004 | WO2004005285A1 New quinuclidine amide derivatives |
| 01/15/2004 | WO2004005282A1 PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES |
| 01/15/2004 | WO2004005281A1 Inhibitors of tyrosine kinases |
| 01/15/2004 | WO2004005277A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 01/15/2004 | WO2004005276A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | WO2004005267A2 Heteroaryl compounds useful in treating inflammatory disorders |
| 01/15/2004 | WO2004005266A1 Oxazole derivatives and their use as insulin sensitizers |
| 01/15/2004 | WO2004005265A1 Quinazoline derivatives |
| 01/15/2004 | WO2004005264A2 Imidazole compounds for the treatment of hepatitis c virus infections |
| 01/15/2004 | WO2004005262A2 New neuropeptide y y5 receptor antagonists |
| 01/15/2004 | WO2004005260A1 A-`7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 01/15/2004 | WO2004005259A1 Drug delivery system of substituted hydroxypyridine compound and conjugate of hydroxypyridine compound |
| 01/15/2004 | WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | WO2004005257A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | WO2004005256A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors |
| 01/15/2004 | WO2004005255A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors |
| 01/15/2004 | WO2004005253A1 Indolin phenylsulfonamide derivatives |
| 01/15/2004 | WO2004005252A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | WO2004005250A1 Hmg-coa reductase inhibitors |
| 01/15/2004 | WO2004005249A1 Pyrrolidine derivatives as oxytocin antagonists |
| 01/15/2004 | WO2004005243A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 01/15/2004 | WO2004005240A1 Process for preparing nateglinide and intermediates thereof |
| 01/15/2004 | WO2004005237A1 Method of preparing hydroxytyrosol esters, esters thus obtained and use of same |
| 01/15/2004 | WO2004005233A1 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
| 01/15/2004 | WO2004005229A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | WO2004005228A1 An hydroxytyrosol-rich composition from olive vegetation water and method of use thereof |
| 01/15/2004 | WO2004005227A1 Crystallization of polyol compositions, crystalline polyol composition product and use thereof |
| 01/15/2004 | WO2004004834A1 Compounds and methods for treating cancer and inflammation |
| 01/15/2004 | WO2004004833A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | WO2004004784A1 A complex of tumor ablation mixture and its use in the preparing drugs for treating tumors |
| 01/15/2004 | WO2004004783A1 Liquid compositions for the oral administration of lorazepam |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents |
| 01/15/2004 | WO2004004777A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors |
| 01/15/2004 | WO2004004776A1 Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | WO2004004775A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | WO2004004774A2 Compositions comprising panthetine for the treatment of dyslipidemia |
| 01/15/2004 | WO2004004773A1 Remedies for respiratory diseases |
| 01/15/2004 | WO2004004771A1 Immunopotentiating compositions |
| 01/15/2004 | WO2004004766A1 MP53S AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 01/15/2004 | WO2004004754A1 Novel medicament combinations based on magnesium salts and fibrinolytics |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004749A1 Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
| 01/15/2004 | WO2004004747A1 Antiflatulent composition, antiflatulent healthy drink and large intestine inside wash fluid |
| 01/15/2004 | WO2004004746A1 Simmondsin for use as an angiogenesis inhibitor |
| 01/15/2004 | WO2004004744A1 Compositions of hyaluronic acid and methods of use |
| 01/15/2004 | WO2004004743A1 Immunostimulation by chemically modified rna |
| 01/15/2004 | WO2004004741A1 Aqueous formulation comprising digestible saccharides with beneficial effects on a tendency to cardiovascular disease |
| 01/15/2004 | WO2004004740A1 Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject |
| 01/15/2004 | WO2004004739A1 Ciclesonide-containing sterile aqueous suspension |
| 01/15/2004 | WO2004004738A1 Remedy or preventive for keratoconjunctival epithelial cell injury |
| 01/15/2004 | WO2004004737A1 Cephalosporin preparation for oral use |
| 01/15/2004 | WO2004004736A1 Novel use of imidazotriazinones |
| 01/15/2004 | WO2004004735A1 Remedy comprising combination of levocabastine with pemirolast |
| 01/15/2004 | WO2004004734A1 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| 01/15/2004 | WO2004004733A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/15/2004 | WO2004004732A1 Quinazoline derivatives for use in the treatment of cancer |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |